Protective effect of rutin supplementation against cisplatin-induced Nephrotoxicity in rats. 2017

Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Kingdom of Saudi Arabia.

BACKGROUND Cisplatin (CP) is commonly used in the treatment of different types of cancer but nephrotoxicity has been a major limiting factor. Therefore, the present study aimed to study the possible protective effect of rutin against nephrotoxicity induced by cisplatin in rats. METHODS Forty male Wistar albino rats were randomly divided into 4 groups. Rats of group 1 control group intraperitoneal (i.p.) received 2.5 ml/kg, group 2 CP group received single dose 5 mg/kg cisplatin i.p. group 3 rutin group orally received 30 mg/kg rutin group 4 (CP plus rutin) received CP and rutin as in group 2 and 3. Kidneys were harvested for histopathology and for the study the gene expression of c-Jun N-terminal kinases (JNK), Mitogen-activated protein kinase 4 (MKK4), MKK7, P38 mitogen-activated protein kinases (P38), tumor necrosis factors alpha (TNF-α), TNF Receptor-Associated Factor 2 (TRAF2), and interleukin-1 alpha (IL-1-α). RESULTS The cisplatin single dose administration to rats induced nephrotoxicity associated with a significant increase in blood urea nitrogen (BUN) and serum creatinine and significantly increase Malondialdehyde (MDA) in kidney tissues by 230 ± 5.5 nmol/g compared to control group. The animal treated with cisplatin showed a significant increase in the expression levels of the IL-1α (260%), TRFA2 (491%), P38 (410%), MKK4 (263%), MKK7 (412%), JNK (680%) and TNF-α (300%) genes compared to control group. Additionally, histopathological examination showed that cisplatin-induced interstitial congestion, focal mononuclear cell inflammatory, cell infiltrate, acute tubular injury with reactive atypia and apoptotic cells. Rutin administration attenuated cisplatin-induced alteration in gene expression and structural and functional changes in the kidney. Additionally, histopathological examination of kidney tissues confirmed gene expression data. CONCLUSIONS The present study suggested that the anti-oxidant and anti-inflammatory effect of rutin may prevent CP-induced nephrotoxicity via decreasing the oxidative stress, inhibiting the interconnected ROS/JNK/TNF/P38 MAPK signaling pathways, and repairing the histopathological changes against cisplatin administration.

UI MeSH Term Description Entries
D008297 Male Males
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012431 Rutin A flavonol glycoside found in many plants, including BUCKWHEAT; TOBACCO; FORSYTHIA; HYDRANGEA; VIOLA, etc. It has been used therapeutically to decrease capillary fragility. 3-Rhamnosyl-Glucosyl Quercetin,Quercetin-3-Rutinoside,Rutoside,Quercetin 3 Rutinoside,Quercetin, 3-Rhamnosyl-Glucosyl
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D058186 Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions. Acute Kidney Failure,Acute Kidney Insufficiency,Acute Renal Failure,Acute Renal Injury,Acute Renal Insufficiency,Kidney Failure, Acute,Kidney Insufficiency, Acute,Renal Failure, Acute,Renal Insufficiency, Acute,Acute Kidney Failures,Acute Kidney Injuries,Acute Kidney Insufficiencies,Acute Renal Failures,Acute Renal Injuries,Acute Renal Insufficiencies,Kidney Failures, Acute,Kidney Injuries, Acute,Kidney Injury, Acute,Kidney Insufficiencies, Acute,Renal Failures, Acute,Renal Injuries, Acute,Renal Injury, Acute,Renal Insufficiencies, Acute

Related Publications

Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
December 2019, Journal of advanced veterinary and animal research,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
July 2008, Pakistan journal of pharmaceutical sciences,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
January 2019, Pakistan journal of biological sciences : PJBS,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
April 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
January 2013, Indian journal of pharmacology,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
July 2016, Canadian journal of physiology and pharmacology,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
November 2012, BMC complementary and alternative medicine,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
August 2014, Human & experimental toxicology,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
June 2002, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP,
Ali R Alhoshani, and Mohamed M Hafez, and Sufia Husain, and Abdel Malek Al-Sheikh, and Moureq R Alotaibi, and Salim S Al Rejaie, and Musaad A Alshammari, and Mashal M Almutairi, and Othman A Al-Shabanah
January 2016, Avicenna journal of phytomedicine,
Copied contents to your clipboard!